|Stage of funding:||Current|
ReVision Optics®, Inc., (RVO) is a privately held corporation headquartered in Southern California, USA.
ReVision Optics focuses on the research and development of innovative optical solutions dedicated to presbyopic vision correction. ReVision’s Raindrop™ Near Vision Inlay offers a unique, patented refractive surgery solution. The inlay is designed to improve the near vision that has been lost by the eye’s natural aging process called presbyopia. This is a new technology in refractive eye surgery whereby a corneal inlay made of a hydrogel is implanted just beneath the surface of the eye. The Raindrop inlay provides an ideally suited surgical option for near and intermediate vision enhancement.
ReVision’s approach harnesses cutting edge technology. The outpatient procedure is completed in a few minutes and near eyesight is quickly recovered within the first several days. The inlay is invisible, easily implanted, minimally invasive and the surgery is reversible.
Revision’s Raindrop is currently in a prospective, multicenter U.S. FDA regulated Phase III clinical trial that is evaluating the safety and effectiveness of the device. Clinical results thus far indicate a significant improvement in near and intermediate vision after the surgery and persistence of results for a long period of time.
Funds raised in this round of investment will be used to complete the U.S. FDA trial, expand ReVision’s commercial efforts outside the US and to undertake clinical trials in Russia, leading to registration and commercialization of the product.
What is Raindrop Made Of?
The Raindrop™ Near Vision Inlay is a lens made up of nearly 80% water. It’s like a drop of water, completely clear and so small, no one will ever know you have it – not even you!
How Does Raindrop Work?
Raindrop gently changes the curvature of your eye, allowing you to see clearly when looking at objects up close as well as at intermediate and far distances.
Its placement allows light to focus correctly on the retina, dramatically improving your near vision.
20 May 2013
Российские власти ставят перед собой задачу довести долю отечественного производства в фармацевтике до 50%, а в фармацевтической и медицинской технике — до 40%. Об этом сегодня на Первом российско-швейцарском дне инноваций выступил заместитель главы Минпромторга РФ Игорь Караваев.